Gilead Sciences Inc. (GILD)

GILD · Health Care · United States

Gilead Sciences Inc. (GILD) is a company in the Health Care sector, based in United States. The stock is held in 25 ETFs we track – with its largest weight of 2.99 % in XUHL (msci-usa-health-care). Anyone holding one of these ETFs also owns a small indirect stake in Gilead Sciences.

Very high ETF coverage: 25 of the 95 ETFs we cover hold Gilead Sciences, spread across 13 indices. That puts the stock in more ETFs than 93.9 % of the 4,334 stocks we cover.

Held in25 ETFs

Highest weight2.99 %

Indices13

SectorHealth Care

CountryUnited States

ISINUS3755581036

WKN885823

Data note 1

Price chart

Data note 2

Performance

Performance
Year to date	+20.3 %	1 year	+33.2 %
1 month	+6.3 %	3 months	+17.7 %
Calendar year 2025	+32.9 %

52W

Data note 3

Measured in euros, Gilead Sciences returned +22.5 % year to date and +36.3 % over one year. The gap to the dollar figures above comes from the exchange rate alone: each daily price is converted at the ECB euro reference rate for the same day.

Data note 4

Risk metrics

Max drawdown-22.0 %

Volatility p.a.26.8 %

Data note 5

Below peak-5.2 %

Beta to S&P 5000.33

Correlation to S&P 5000.16

The close on Sep 16, 2026 was 5.2 % below the highest close since Jul 11, 2024, reached on Feb 11, 2026. Over the last 252 trading days, on days when the S&P 500 rose or fell 1 %, Gilead Sciences moved on average 0.33 % in the same direction. The correlation of 0.16 shows how reliable that average is: the broad market explained only a small share of the daily moves.

Data note 6

Correlated with

The strongest co-movers on top, the most inverse below. Low or negative values improve portfolio diversification.

Correlated with
Instrument	r	−1 … +1
Amgen Inc.	+0.56
Bristol-Myers Squibb Company	+0.55
Royalty Pharma Plc Class A	+0.55
Pfizer Inc.	+0.53
Vertex Pharmaceuticals Incorporated	+0.51
AbbVie Inc.	+0.45
Seagate Technology Holdings plc	-0.41
Lumentum Holdings Inc.	-0.35
GRAM	-0.34

Data note 7

Key financials

Latest reported fiscal year (FY2025, period end 2025-12-31) as filed with the SEC.

Revenue29.4 bn $

Net income8.5 bn $

Diluted EPS6.78 $

Net margin28.9 %

Return on equity37.5 %

Equity ratio38.5 %

Revenue growth+2.4 %

Revenue and profit by fiscal year
Fiscal year	Revenue	Net income	Margin
FY2023	27.1	5.7	20.9 %
FY2024	28.8	0.5	1.7 %
FY2025	29.4	8.5	28.9 %

Data note 8

Held in these ETFs

Held in these ETFs
ETF	Index	Weight	per €1,000 in the ETF
XUHL / XUHC	msci-usa-health-care	2.99 %	€29.90
XDWH	msci-world-health-care	2.20 %	€22.00
SPFS	msci-world-health-care	2.20 %	€22.00
2B7K	msci-world-sri	0.86 %	€8.60
EXXT	nasdaq-100	0.82 %	€8.20
XNAS	nasdaq-100	0.82 %	€8.20
XDEV	msci-world-value	0.45 %	€4.50
XDEQ	msci-world-quality	0.44 %	€4.40
XDEB	msci-world-minimum-volatility	0.38 %	€3.80
SPYL / SPY5	sp500	0.28 %	€2.80
SXR8	sp500	0.28 %	€2.80
XD9U / XD9D	msci-usa	0.28 %	€2.80
SWWD	msci-world	0.20 %	€2.00
EUNL	msci-world	0.20 %	€2.00
SPPW	msci-world	0.20 %	€2.00
XDWD / XDWL	msci-world	0.20 %	€2.00
SPYI / SPSA	msci-acwi-imi	0.19 %	€1.90
WIMI	msci-world-imi	0.18 %	€1.80
SPYY	msci-acwi	0.18 %	€1.80
IUSQ	msci-acwi	0.18 %	€1.80

Data note 9

The last column turns the weight into euros: this much of €1,000 invested in one of these funds is allocated to Gilead Sciences as of the fund's latest holdings list.

Weight in EUNL since 2019

Sep 30, 2019Sep 16, 2026

In EUNL, a fund tracking the MSCI World, Gilead Sciences had a weight of 0.20 % on Sep 30, 2019 and 0.20 % on Sep 16, 2026. Its share peaked at 0.27 % on Mar 31, 2020. The weight rises and falls with the stock's price relative to the other index members, and it also shifts when the index provider changes the composition.

Data note 10

How much Gilead Sciences Inc. overlaps with other holdings in a portfolio is shown by the Portfolio X-Ray and the ETF overlap check.

Stocks with similar ETF exposure

Names that reach a portfolio through largely the same funds as Gilead Sciences — the figure counts the ETFs holding both.

Data note 11

Key figures side by side

Key figures compared with stocks of similar ETF exposure
Stock	1 year	Volatility p.a.	Net margin	Revenue growth
Gilead Sciences	+33.2 %	26.8 %	28.9 %	+2.4 %
Vertex Pharmaceuticals Incorporated	+31.1 %	32.0 %	32.9 %	+8.9 %
IDEXX Laboratories	-20.4 %	37.1 %	24.6 %	+10.4 %
Amgen	+37.8 %	27.7 %	21.0 %	+10.0 %
Incyte Corporation	+48.7 %	34.3 %	25.0 %	+21.2 %
Regeneron Pharmaceuticals	+34.7 %	35.8 %	31.4 %	+1.0 %
DexCom	+14.1 %	41.2 %	17.9 %	+15.6 %
Cigna Group	-4.7 %	30.7 %	2.2 %	+11.2 %
Elevance Health	+33.1 %	35.3 %	2.8 %	+12.5 %

Return and volatility from our daily closing prices in US dollars; margin and growth from the latest SEC annual filing. Fiscal years do not all end on the same date.